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Abstract. The cytotoxic effect of anticancer drugs has been
shown to involve induction of apoptosis. This observation
raises the possibility that factors affecting caspase activation
might be important determinants of anticancer drug sensitivity.
Ectopic expression of caspase-1 has been shown to trigger
apoptosis. However, the role of caspase-1 in apoptosis is now
considered as minor compared to other caspases. In patients,
high levels of caspase-1 expression may be associated with
spontaneous regression in neuroblastomas and with a good
clinical response to chemotherapy in acute myeloid leukemia
and osteosarcoma. In experimental therapeutics for cancer,
caspase-1 has been related to some anticancer activity. These
observations led us to examine the effect of over-expression
on the response to chemotherapy and radiotherapy in vitro
and in vivo. Caspase-1 expression mediated by an adenoviral
vector was able to kill directly cells and to sensitise the
remaining cells to cisplatin or Á-radiation in vitro. In HeLa
cells stably transfected with caspase-1, sensitisation to
cisplatin was due to an amplification of the cisplatin-induced
mitochondrial apoptotic pathway activation. Caspase-1
mediated sensitisation to cisplatin and Á-radiation was also
observed in vivo. Altogether, we conclude that caspase-1 can
act as a radio- and chemo-sensitiser, in vitro and in vivo.
Introduction
Apoptosis can be initiated by a variety of stimuli, including
growth factors, UV, Á-irradiation, or chemotherapeutic drugs.
This phenomenon is co-ordinated by a family of cysteine
proteases, the caspases. They mediate proteolysis of certain
target proteins that ultimately result in cell death. There are
two major intracellular caspase cascades: one activated pre-
dominately by death receptor ligands and the other triggered
by various cellular stresses, including DNA damage and
microtubule disruption (1).
The cytotoxic effect of anticancer drugs has been shown
to involve induction of apoptosis (2). This observation raises
the possibility that factors affecting caspase activation and
activity might be important determinants of anticancer drug
sensitivity (3). For example, it has been demonstrated that
inhibition of caspases was associated with resistance to chemo-
therapy in vivo (4). In particular, apoptosis induced in tumour
cells by cytarabine, doxorubicin, methatrexate (5), cisplatin
(6), ionizing radiation (7) or taxotere (8) required the
activation of caspase-1 and -3 for induction of cell death.
Ectopic expression of caspase-1 has been shown to trigger
apoptosis. However, the role of caspase-1 in apoptosis has
been revisited and it is now considered minor compared to
caspase-3, -6, -7, -8, -9 (1).
The potential of caspase-1 in experimental therapeutics
for cancer has been demonstrated: ICE was delivered by
recombinant retrovirus (9), adenovirus (10) or via a gene gun
(11).
In clinical studies, it has been suggested that caspase-1
may be associated with spontaneous regression of neuro-
blastomas (12). In addition, the correlation between the level
of caspase-1 expression and the response to chemotherapy
appears to depend on the type of cancer studied. In acute
myeloid leukemia (13), and osteosarcoma (14), high expression
of caspase-1 is correlated with a good clinical response to
chemotherapy while high levels of serum caspase-1 are
associated with non-response to biochemotherapy in melanoma
(15).
These apparently conflicting data, as well as the potential
of caspase-1 as a therapeutic target, led us to examine the
effect of caspase-1 over-expression on its own and in
combination with chemotherapy and radiotherapy in a panel
of cell lines.
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Materials and methods
Plasmids. Caspase-1 cDNA was amplified by PCR with the
following set of primers (forward primer: 5'-CGGGGTACC
CCATGGCCGACAAGGTCCTG-3' and reverse primer: 5'-
CTAGTCTAGATGCCCACAGACATTC-3') using the ICE-
pBluescript vector (kindly gived by Dr Fueyo) as a template.
The PCR product was cloned into pEF6/V5-His-TOPO
vector (Invitrogen, UK) and sequenced. One clone with the
cDNA inserted in the correct orientation was chosen. In
transfection experiments, an empty pEF6/V5-His-TOPO
vector was used as a control.
The caspase-1 cDNA was inserted into the EcoRV/KpnI
sites of pShuttle (16) to generate pSh-ICE. Once linearised
with PmeI, pSh-ICE was then recombined with pAdeasy1
as previously described to generate pAd-ICE. Correct
recombinants were selected by restriction endonuclease
digestion.
Adenoviral vectors. Ad-GFP, was obtained from Qbiogene
(Cambridge, UK), and Ad-Mock was an E1-deleted Ad-5
vector containing no transgene (17). The virus Ad-ICE was
generated after transfection of pAd-ICE into 293 cells. It
was produced, purified and titrated as previously described
(18).
Cell lines. Cervical carcinoma cell line HeLa, pancreatic cell
lines Panc-O2, HPAF and Panc-1 and the human prostate
cancer cell lines DU-145, PC-3, BHP-1, LNCaP, were obtained
from the Research Cell Service of Cancer Research-UK. Cells
were grown on DMEM or RPMI-1640 medium containing
10% fetal bovine serum in presence of antibiotics.
HeLa cells (105) per well, were transfected with 0.4 μg of
DNA in 6-well plates using Effectene transfection reagent
(Qiagen, UK), according to the manufacturer's protocols with
minor modifications, in order to construct HeLa-Topo and
HeLa-ICE cell lines. Blasticidin S HCl (Invitrogen) resistant
clones, were selected at doses of 10 μg/ml.
Caspase-1 enzymatic assay. p45-proICE is found in normal
HeLa cells but does not form the active protease (19).
Caspase-1 enzymatic activity was assayed using the caspase-1/
ICE Colorimetric Protease Assay kit (MBL, Japan) according
to the manufacturer's instructions, based on the cleavage of
the YVAD-pNA substrate in the presence or absence of the
caspase-1 selective inhibitor YVAD-FMK.
In vitro cytotoxicity assay. Cell lines (2x104 cells), were plated
onto 24-well plates with 1 ml of DMEM with 10% serum,
with the only exception of the radiation experiments where
103 cells per well were seeded. Twenty-four hours later, cells
were infected with 1-10 p.f.u. per cell, and the next day,
different concentrations of cisplatin (Sigma-Aldrich, UK),
paclitaxel (Taxol, Calbiochem, CA), or Á-radiation were
administered. For experiments on HeLa-Topo or HeLa-ICE,
the treatment started 24 h after seeding of the cells. Five or
seven days (for irradiation experiments) after the treatment
started, 100 μl of MTT was added (5 mg/ml) (Sigma-Aldrich).
The cells were incubated for 2 h at 37˚C, dissolved in DMSO
and the optical density at 540 nm was measured.
Flow cytometry. HeLa-Topo or HeLa-ICE cells (106) were
plated onto 6-cm diameter dishes and treated with cisplatin
(1 μg/ml). At different times, cells were washed with PBS,
and harvested. Protocol was followed as previously described
(17), and samples were passed through a filter cap immediately
prior to analysis on a FACSCalibur™ (Beckton-Dickinson).
Western blots. HeLa-Topo or HeLa-ICE cells (106) were plated
onto 6-cm diameter tissue culture dishes. The next day, cells
were treated with 0, 0.3 or and 1 μg/ml of cisplatin and
collected after 18 h of treatment. Cells and supernatant were
pelleted, and 100 μl of lysis buffer (150 mm NaCl, 50 mM
Tris pH 7.5, 0.05% SDS, 1% Triton X-100) was added. The
resulting homogenate was sonicated on ice.
Protein extract (20 μg) was separated on 10-15% SDS-
polyacrylamide gels and transferred onto nitrocellulose filters
by semidry blotting. The primary antibodies used were
mouse monoclonals anti-PARP IgG (1:2000) (Santa Cruz)
and anti-caspase 8 IgG (1:1000) (Alexis Biochemicals, UK),
a rabbit polyclonal anti-caspase-9 (1:500) (Santa Cruz, UK),
and mouse monoclonal anti-GFP 3E1 (1:4000) (Cancer
Research-UK Monoclonal Antibody Services). Secondary
antibodies were a rabbit anti-mouse (1:1500) or a goat anti-
rabbit (1:1500) HRP conjugated from Sigma. Antibody binding
was visualized using ECL (Amersham Pharmacia Biotech,
UK).
Real-time PCR. HeLa Topo or HeLa-ICE cells (106) were
plated onto 6-cm diameter tissue culture dishes. The next
day, cells were treated with 0, 0.3, 0.5 or 1 μg/ml cisplatin and
collected after 18 h of treatment. RNA was extracted using
TRIzol (Invitrogen) according to the manufacturer's protocol.
Total RNA was resuspended in 100 μl RNAse-free water and
RNA (2 μg) was reverse transcribed using TaqMan reverse
transcription reagents kit (ABI), as previously described (20).
Forward and reverse primers for cIAP-1, cIAP-2, XIAP
and PGK-1 (endogenous control) were designed using Primer
express software and used at a concentration of 300 nm/
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Figure 1. Effect of Ad-ICE infection on cell viability. Cells (2x104), were
plated onto 24-well plates and allowed to growth 24 h before infected with
Ad-ICE or Ad-Mock in a range of doses between 1-10 plaque-forming units
(p.f.u.) per cell. For each cell line, the dose of virus used was enough to infect
100% of the cells. Cell viability was measured 5 days post-infection by MTT
assay. The % of cell survival is the % of the number of live cells infected by
Ad-ICE related to the number of live cells after infection with Ad-Mock.
Each experiment was performed in triplicate.
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In vivo studies. HeLa-Topo or HeLa-ICE cells (106) were
injected subcutaneously into 6-week-old female Balb/c nude
mice. Experiments were conducted after appropriate local
ethical approval. Nude mice were obtained from Harlan Iberica
(Barcelona, Spain) and were kept in a germ-free environment
with irradiated food and acidified water ad libitum. When a
tumour reached 0.2 cm2, groups of mice received a single
intraperitoneal injection of cisplatin (Bristol-Myers-Squibb)
of 1, 4, 7 or 10 mg/kg of weight, or PBS injection for controls.
For radiotherapy experiments, treated mice received semi-
corporal irradiation in an AECL Cobalt unit, at a skin surface
distance of 80 cm and a radiation coefficient of 136 cGy/min.
They received daily doses of 600 cGy up to a total of 12 Gy.
The upper body was covered and the fractioning of the
irradiation was chosen to minimize the toxicity produced
by the irradiation. Tumour size was determined by two
perpendicular measurements every other day, until the
tumour size reached the limit authorised by the local ethical
approval.
Results
Expression of caspase-1 mediated by an adenoviral vector in
cell lines of different origins. Immunohistochemical studies
showed that the majority of primary prostate cancer cells
lacked caspase-1 protein expression compared with normal
prostatic tissue (21) but on the contrary, over-expression of
caspase-1 is observed in most of pancreatic cancer cells
compared with normal pancreatic tissue (22).
In order to assess whether the responses to caspase-1
were tumour type-specific, we infected a panel of prostatic
(DU-145, PC-3, BHP-1 or LNCaP), pancreatic (Panc-O2,
Panc-1, HPAF) and cervical (HeLa) carcinoma cell lines with
an adenovirus encoding caspase-1. For each cell line, the dose
of virus used was determined by Ad-GFP which ensured
100% cell transfection without non-specific viral toxicity
(data not shown).
Infection with Ad-ICE produced a marked decrease of
survival in most of the cell lines 3 days after infection,
compared with uninfected control (data not shown) or with
an identical adenovirus without caspase-1 expression (Fig. 1).
These results were observed on all the cell lines tested, but
even in the most sensitive cell line (LNCaP), some cells
resistant to caspase-1 remained (Fig. 1).
Adenoviral expression of caspase-1 sensitises cells to anti-
cancer treatments in vitro. To test the radio or chemo-
sensitization produced by ICE over-expression after adeno-
viral infection, various cell lines were incubated for 5 or 7
days with several doses of cisplatin or Á-radiation.
Fig. 2 shows that the extent of the effect of Á-radiation or
cisplatin depends on the cell line studied. However, all cells
infected with Ad-ICE showed a marked sensitization to
different treatments compared with non-infected cells or
infected with mock adenovirus.
Generation of a cell line over-expressing caspase-1. To
examine further the effect of radio and chemotherapy on
cells not sensitive to caspase-1 action, a HeLa cell line over-
expressing caspase-1 was generated.
The presence of the caspase-1 cDNA in the genome of
HeLa-ICE cells was detected by PCR on genomic DNA and
was absent from the control line HeLa-Topo (data not shown).
Caspase-1 activity was measured on HeLa-Topo and HeLa-
ICE cells treated with 0.3 μg/ml of cisplatin (CDDP). The
specific enzymatic activities were 0.06 absorbance units/mg
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Figure 2. Effect of Ad-ICE infection on radio- and chemo-sensitization in vitro: 2x104 cells (103 cells per well for irradiation experiments), were plated onto
24-well plates and allowed to growth 24 h before infected with Ad-ICE or Ad-Mock in a range of doses between 1-10 plaque-forming units (p.f.u.) per cell.
For each cell line, the dose of virus used was enough to infect 100% of the cells. The day after infection cells were treated with cisplatin (A-C) or radiotherapy
(D-F) and 5 (for CDDP) or 7 days (for radiotherapy) after treatment, cell viability was measured by MTT. Experiments were performed in triplicate for each
cell line and treatment. The data presented are the mean ± SD of three experiments performed in triplicate wells. Diamond, uninfected; square, mock-infected;
triangle, ICE-infected cell line.
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of protein for HeLa-Topo and 0.21 absorbance units/mg of
protein for HeLa-ICE.
To compare their growth potential, both cell lines were
seeded on day 0 and the number of cells was evaluated at
days 1, 5 and 8. Fig. 3A shows that HeLa-ICE cells in vitro
grow significantly more slowly than the control HeLa-Topo.
To determine whether this difference is due to delayed cell
cycle or concomitant cell growth and death of the HeLa-ICE
cells, flow cytometry analysis of both cell lines was performed
(Fig. 3B). No significant difference in the sub-G1 population
(an indicator of apoptosis) was observed in untreated HeLa-
Topo and HeLa-ICE cells (Fig. 3B). By contrast, the number
of cells in G2/M (M4) and S phase (M3) was significantly
increased in HeLa-ICE cells (Fig. 3B). The difference in cell
number observed in Fig. 3A is therefore likely to be the result
of a caspase-1-mediated delayed cell cycle.
Caspase-1 over-expression sensitises HeLa cells to Á-radiation,
in vitro. To assess the effect of caspase-1 over-expression on
the cell death induced by Á-radiation, HeLa-ICE or HeLa-
Topo cells were subjected to various doses of irradiation.
Fig. 4A shows that Á-radiation can kill HeLa-Topo cells, in a
dose-dependent manner. This toxic effect was enhanced in
HeLa-ICE cells. This sensitisation is particularly observed at
a low radiation dose (2 Gy), sufficient to induce the death of
around half of the HeLa-ICE population, while HeLa-Topo
cells remained largely unaffected (Fig. 4A).
Caspase-1 over-expression sensitises HeLa cells to chemo-
therapeutic agents in vitro. The effect of caspase-1 over-
expression on the cell death induced by Taxol was examined
by incubating HeLa-ICE or HeLa-Topo cells with various
concentrations of the drug for 5 days. Fig. 4B shows a dose-
dependent decrease in cell survival of the treated cells, with a
modest but significant increased sensitivity of HeLa-ICE to
Taxol.
By contrast, when these experiments were repeated with
cisplatin (CDDP), a dose-dependent decrease in cell survival
was observed with doses of cisplatin as low as 0.5 μg/ml,
with the entire population of HeLa-ICE cells being killed
with a dose of 3 μg/ml. This effect was accompanied by an
increase in the sub-G1 population, 24 and 48 h after the start
of the treatment with 1 μg/ml of cisplatin (Fig. 3B). These
data suggest that the increased sensitisation to cisplatin
mediated by caspase-1 involves enhancement of apoptosis.
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Figure 3. Effect of caspase-1 over-expression on the growth potential of HeLa
cells. (A) HeLa-Topo (black bars) or HeLa-ICE (white bars) cells (2x104)
were seeded in 24-well plates under standard conditions. Triplicated wells
for each condition were counted on days 1, 5 and 8. The cells reached
confluency on day 10. The data presented are the mean ± SD of three
experiments per-formed. (B) Flow cytometry analysis. HeLa-Topo or HeLa-
ICE cells (106) were treated or not (control) with 1 μg/ml cisplatin. Twenty-
four or 48 h later, cells were trypsinized, fixed in ethanol and stained with
propidium iodide before to be analysed on a FACSCalibur™. The tables
next to each figure show the percentage of cells in each phase of the cell
cycle. M1, sub-G1 population; M2, G0/G1 population; M3, S population;
M4, G2/M.
Figure 4. Effect of treatments on HeLa-Topo or HeLa-ICE cells. (A) Á-
radiation: HeLa-Topo (black bars) or HeLa-ICE cells (white bars) (103)
were seeded in a 24-well plate. Twenty-four hours later, cells were subjected
to different doses of Á-irradiation (see graph). (B and C) Chemotherapeutic
agents: HeLa-Topo (black bars) or HeLa-ICE cells (white bars) (2x104)
were treated with different concentrations of Taxol (B) or cisplatin (C). Five
days after the beginning of the treatment (or 7 for Á-radiation) the number of
viable cells was determined using an MTT assay. For each cell line, 100%
correspond to the number of cells non-treated. The data presented are the
mean ± SD of three experiments performed in triplicate.
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Caspase-1 amplifies cisplatin-induced mitochondrial apoptotic
pathway. In response to a pro-apoptotic stimulus involving
cytochrome-C release from the mitochondria, the 47 kDa pro-
caspase-9 is cleaved into its small (12 kDa) and large (35 kDa)
sub-units. Independently, activation of receptors mediating
cell death (TNF-R1, TNF-R2, death receptor 3 and 4 or
Fas) induce the activation of caspase-8 which result in its
proteolytic cleavage (1). Both apoptotic pathways will
ultimately converge to the activation of effector caspases,
such as caspase-3 that will cleave cellular proteins like the
poly (ADP-ribose)-polymerase (PARP) that is cleaved into
p85 and p25 proteins. Incubation of HeLa-Topo cells with
0.3 or 1 μg/ml of cisplatin led to a very modest cleavage of
caspase-9 that did not result in a significant PARP-cleavage
(Fig. 5A). By contrast, incubation of HeLa-ICE cells with
cisplatin led to a dose-dependent activation of caspase-9
paralleled by a PARP-cleavage (Fig. 5A). Under similar
treatment, caspase-8 remained unaffected in both cell lines,
indicating that caspase-1 over-expression amplifies the
cisplatin-induced mitochondrial apoptotic pathway, without
affecting the ligand-induced apoptotic pathway. Interestingly,
this effect on the apoptotic cascade was accompanied by an
increase in the levels of transcripts of the inhibitors of apoptosis
such as XIAP, cIAP1 and -2 (Fig. 5B).
Caspase-1 as a chemo- and radio-sensitiser in vivo. To
determine whether the caspase-1-mediated sensitisation
obtained in vitro (Fig. 4) could be observed in vivo, HeLa-
Topo or HeLa-ICE cells were injected subcutaneously in
nude mice and the animals were treated with increasing doses
of cisplatin (4 and 10 mg/kg weight) (Fig. 6A and B) or
radiotherapy (Fig. 6C) when the tumours reached 0.2 cm2. In
both experiments, we observed that HeLa-Topo tumours
grew faster in vivo than HeLa-ICE tumours (data not shown),
as suggested by their growth rate in vitro (Fig. 3A). Intra-
peritoneal administration of 4 or 10 mg/kg cisplatin led to an
inhibition of tumour growth in HeLa-Topo tumours (Fig. 6A
and B). This effect was dramatically increased when HeLa-
ICE-bearing animals were subjected to the same treatment,
with tumours reducing by >90% 7 days after a single admini-
stration of 10 mg/kg weight of cisplatin (Fig. 6B). In the
same group 3/8 tumours remained undetectable when the
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Figure 5. Caspase and IAP analysis on HeLa-Topo and HeLa-ICE cell lines.
(A) Western blot analysis of HeLa-Topo and HeLa cell lines treated with
cisplatin. HeLa-Topo or HeLa-ICE cells (106) were plated onto 6-cm
diameter tissue culture dishes, treated the next day with different doses of
cisplatin (see figure) and collected after 18 h of treatment. Cells and
supernatant were pelleted, lysed and sonicated on ice. Twenty micrograms
of protein extract was separated on SDS-polyacrylamide gels and transferred
onto nitrocellulose filters. Monoclonals for anti-PARP IgG, anti-caspase-8
IgG and a rabbit polyclonal for anti-caspase-9 were used. (B) Real-time PCR
analysis of inhibitors of apoptosis in HeLa-Topo and HeLa-ICE cell lines.
HeLa-Topo or HeLa-ICE cells (106) were plated onto 6-cm diameter tissue
culture dishes. The next day, the cells were treated with 0, 0.3, 0.5 or 1 μg/ml
cisplatin and collected after 18 h of treatment. RNA (2 μg) was reverse-
transcribed to perform real-time PCR reactions for cIAP-1, cIAP-2, XIAP and
PGK-1 (endo-genous control, data not shown). Samples from three separate
experiments were analysed in triplicate.
Figure 6. Effect of cisplatin and Á-radiation in HeLa-Topo and HeLa-ICE
cells in vivo. One million HeLa-Topo or HeLa-ICE cells were injected sub-
cutaneously into 6-week-old female Balb/c nu/nu mice. Tumours were
treated (A and B) with cisplatin (CDDP) at doses of 4 or 10 mg/kg weight or
PBS for the controls, or (C) with Á-radiation on 2 consecutive days (two
doses leading to a total of 12 Gy), when they reached approximately the size
of 0.2 cm2. For both groups, the size at the start of the treatment was HeLa-
Topo 0.21 ± SD: 0.05 and HeLa-ICE 0.2 ± SD: 0.06, respectively. The tumour
sizes were measured every other day. These values represent an average of
at least 8 tumours. For each time point, the size of the tumour treated is
divided by the size of the non-treated tumour and this result is multiplied by
100. This value is then substracted to 100% to obtain the tumour growth
inhibition presented.
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experiment was stopped. Dose-dependent response was
obtained when doses of 1 and 7 mg/kg weight were injected
(data not shown).
Similarly, two sessions of radiotherapy when the tumours
reached around 0.2 cm2, on 2 consecutive days (to a total of
12 Gy) led to a reduction in the rate of tumour growth in HeLa-
Topo-bearing animals (Fig. 6C). Greater tumour regression
was observed when HeLa-ICE-bearing animals were subjected
to the same treatment (Fig. 6C), with 3/8 tumours remaining
undetectable when the experiment was stopped.
Discussion
In the present study, we report that over-expression of
caspase-1 by adenovirus is capable of killing a proportion of
the cells infected. In addition, we show that the surviving
cells expressing caspase-1 have increased sensitivity to radio-
therapy and chemotherapy in vitro. This sensitisation appeared
to be quantitatively more important when DNA-damaging
agents (as cisplatin and Á-radiation) were used as opposed
to a drug affecting microtubules like Taxol. In the case of
sensitisation to cisplatin, the effect of caspase-1 is accompanied
by an increase in mRNA levels of anti-apoptotic molecules
such as XIAP and cIAP1 and cIAP2. Finally caspase-1 can
sensitise HeLa cells to cisplatin or Á-radiation in vivo.
These data are in agreement with some clinical results
associating caspase-1 with a favourable response to chemo-
therapy: in acute myeloid leukemia, high expression of
caspase-1 indicated a good clinical response to chemotherapy
(13) or a favourable prognosis; high levels of caspase-1 have
been correlated with spontaneous regression in neuroblastoma
(12). Also, the serum concentration of caspase-1 in high-
grade osteosarcoma patients has been shown to correlate with
a good response to chemotherapy (14). Similarly, high levels
of expression of caspase-1 observed in low-grade astroglial
tumours were seen in apoptotic areas of the tumours and that
was correlated with longer survival (23). An immunohisto-
chemical study revealed that the majority of primary prostate
cancer lacked caspase-1 immunoreactivity whereas the
remaining showed reduced expression compared with normal
prostate (21). This set of data suggests that caspase-1 expression
is probably negatively selected during the establishment of a
primary prostate tumour.
By contrast, increased caspase-1 expression has been
associated with a poorer prognosis in other types of malig-
nancy. In pancreatic cancer, over-expression of caspase-1 is
observed in a majority of cells, whereas normal pancreatic
tissue shows only occasional immunoreactivity (22), suggesting
an additional function of caspase-1 besides apoptosis to
promote pancreatic malignancy.
Several proteins have already been suggested as radio-
and/or chemo-sensitisers to cancer cells, some of them are
currently being used in gene therapy clinical trials. In this
respect, adenovirus-mediated delivery of p53 tumour sup-
pressor gene is the best-documented and multiple evidence
suggest that alteration of p53 functions result in reduced
responses to anticancer agents (24). Therefore, replacement
therapy using p53, in combination with DNA-damaging
agents is a strategy currently developed in a growing number
of malignancies, for which local disease control remains
sub-optimal. The adenovirus type 5 E1A protein and some
mutants generated from it were also shown to sensitise
carcinoma cells to radio- and chemo-therapy in a p53-
independent manner in vitro and in vivo in murine and
human tumour models (25).
Previous studies on some of the cell lines that we used in
the present work, were employed to correlate the sensitivity
or resistance of the different cell lines to anticancer treatments
with genetic factors described in the literature (26). Some
of these genetic pathways involved genes such as different
members of the IAP family (cIAP1 and 2, XIAP), mutations
in p53, pro- and anti-apoptotic members of the Bcl-2 family
(Bax, Bcl-2 or Bcl-xl), the androgen dependency or not, or
the intrinsic status of caspase-1. Neither the kind of tumour
or any of the studied factors, including caspase-1 expression
was correlated with the response showed by the cell lines to
treatments.
Caspase-1 has already demonstrated some effect in
experimental therapeutics for cancer. Retroviral- (4) and
adenoviral-mediated delivery (10) of caspase-1 induced
apoptosis that correlated in vivo with an anti-tumour effect.
Combined with our observations, these data demonstrate the
potential of caspase-1 for cancer gene therapy protocols where
caspase-1 gene delivery could be used in combination with
chemotherapy or radiotherapy.
In conclusion, we propose to use caspase-1 as a radio-
and chemo-sensitiser in cancer gene therapy protocols,
possibly combining the vectors with tumour/tissue selective
promoters to avoid the effect in other tissues. The tumour
target would be ideally accessible and treatable by either or
both types of agents. In this context, primary prostate cancer
appears to be a suitable candidate disease as in addition to
prostate selective promoters, caspase-1 expression is lost
(21). This local treatment of an accessible primary tumour
site could be complemented by immunotherapy in which
caspase-1 could also be a key player interfering with the
development of distant metastatic disease.
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